Granite Investment Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Granite Investment Partners’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-25,865	Closed	-$149K	–	354
2018 Q4	$149K	Hold	25,865	–	–	0.01%	328
2018 Q3	$351K	Hold	25,865	–	–	0.02%	271
2018 Q2	$307K	Hold	25,865	–	–	0.02%	275
2018 Q1	$291K	Sell	25,865 -96,779	-79%	-$847K	0.02%	266
2017 Q4	$819K	Hold	122,644	–	–	0.05%	245
2017 Q3	$1M	Sell	122,644 -63,934	-34%	-$399K	0.06%	212
2017 Q2	$838K	Sell	186,578 -8,993	-5%	-$47K	0.06%	250
2017 Q1	$1.08M	Buy	+195,571	New	+$855K	0.07%	224

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Granite Investment Partners's ADAP Position: Q1 2019 in Review

Granite Investment Partners sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 25,865 shares — an estimated $149K sold.

Granite Investment Partners first reported a position in ADAP in Q1 2017 and held it in 8 quarters. The position peaked at $1.08M in Q1 2017. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

Granite Investment Partners reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
Granite Investment Partners sold 25,865 Adaptimmune Therapeutics shares in Q1 2019, an estimated $149K.
Granite Investment Partners first reported a position in Adaptimmune Therapeutics in Q1 2017 and held it in 8 quarters.
Granite Investment Partners's Adaptimmune Therapeutics position peaked at $1.08M in Q1 2017.
68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Granite Investment Partners's 13F filing for Q1 2019, filed 13 May 2019.